What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature

Eric Lu, Joseph Shatzel, Florence Shin, Vinay Prasad

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The phrase “unmet medical need” has important regulatory implications, but there is no empirical analysis of its real world usage. We sought to determine the annual US incidence, 5-year survival, and number of National Comprehensive Cancer Network (NCCN)-recommended regimens for indications described in the literature as an “unmet medical need.” We queried Google Scholar to identify publications where authors used the phrase “unmet medical need” to refer to a specific cancer indication. For each indication, we investigated the annual US incidence, 5-year survival, and number of NCCN recommended regimens. We identified 237 cancer indications considered by authors an “unmet medical need.” The term was found most frequently appended to breast cancer indications comprising 30 of the 237 citations (12.7%). This was followed by lung 24/237 (10.1%), hepatocellular 18/237 (7.6%), and prostate cancer 13/237 (5.4%). In 55 of 237 (23.2%) instances where an indication was described by the authors as an unmet medical need, the incidence was 1,000 cases per year, there were five regimens recommended by NCCN, and there was a 50% or greater 5-year survival. Forty-three of 237 (18.1%) indications had at least an incidence of 10,000 cases a year, 10 recommended regimens, and a 50% 5-year survival. In conclusion, “unmet medical need” has been used to describe cancer indications that are rare, and have few options and poor survival outcomes. However, the term has also been used to describe indications that occur commonly, have many treatment alternatives, and are clinically indolent with more encouraging expectations for survival. Some standardization is needed.

Original languageEnglish (US)
Pages (from-to)8-12
Number of pages5
JournalSeminars in Oncology
Volume44
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

Neoplasms
Incidence
Publications
Prostatic Neoplasms
Breast Neoplasms
Lung

Keywords

  • Cancer drug approval
  • Regulation
  • Unmet medical need
  • US FDA

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature. / Lu, Eric; Shatzel, Joseph; Shin, Florence; Prasad, Vinay.

In: Seminars in Oncology, Vol. 44, No. 1, 01.02.2017, p. 8-12.

Research output: Contribution to journalArticle

@article{2ce900ecda4f4f8c8f25feaca3a31ed8,
title = "What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature",
abstract = "The phrase “unmet medical need” has important regulatory implications, but there is no empirical analysis of its real world usage. We sought to determine the annual US incidence, 5-year survival, and number of National Comprehensive Cancer Network (NCCN)-recommended regimens for indications described in the literature as an “unmet medical need.” We queried Google Scholar to identify publications where authors used the phrase “unmet medical need” to refer to a specific cancer indication. For each indication, we investigated the annual US incidence, 5-year survival, and number of NCCN recommended regimens. We identified 237 cancer indications considered by authors an “unmet medical need.” The term was found most frequently appended to breast cancer indications comprising 30 of the 237 citations (12.7{\%}). This was followed by lung 24/237 (10.1{\%}), hepatocellular 18/237 (7.6{\%}), and prostate cancer 13/237 (5.4{\%}). In 55 of 237 (23.2{\%}) instances where an indication was described by the authors as an unmet medical need, the incidence was 1,000 cases per year, there were five regimens recommended by NCCN, and there was a 50{\%} or greater 5-year survival. Forty-three of 237 (18.1{\%}) indications had at least an incidence of 10,000 cases a year, 10 recommended regimens, and a 50{\%} 5-year survival. In conclusion, “unmet medical need” has been used to describe cancer indications that are rare, and have few options and poor survival outcomes. However, the term has also been used to describe indications that occur commonly, have many treatment alternatives, and are clinically indolent with more encouraging expectations for survival. Some standardization is needed.",
keywords = "Cancer drug approval, Regulation, Unmet medical need, US FDA",
author = "Eric Lu and Joseph Shatzel and Florence Shin and Vinay Prasad",
year = "2017",
month = "2",
day = "1",
doi = "10.1053/j.seminoncol.2017.02.009",
language = "English (US)",
volume = "44",
pages = "8--12",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature

AU - Lu, Eric

AU - Shatzel, Joseph

AU - Shin, Florence

AU - Prasad, Vinay

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The phrase “unmet medical need” has important regulatory implications, but there is no empirical analysis of its real world usage. We sought to determine the annual US incidence, 5-year survival, and number of National Comprehensive Cancer Network (NCCN)-recommended regimens for indications described in the literature as an “unmet medical need.” We queried Google Scholar to identify publications where authors used the phrase “unmet medical need” to refer to a specific cancer indication. For each indication, we investigated the annual US incidence, 5-year survival, and number of NCCN recommended regimens. We identified 237 cancer indications considered by authors an “unmet medical need.” The term was found most frequently appended to breast cancer indications comprising 30 of the 237 citations (12.7%). This was followed by lung 24/237 (10.1%), hepatocellular 18/237 (7.6%), and prostate cancer 13/237 (5.4%). In 55 of 237 (23.2%) instances where an indication was described by the authors as an unmet medical need, the incidence was 1,000 cases per year, there were five regimens recommended by NCCN, and there was a 50% or greater 5-year survival. Forty-three of 237 (18.1%) indications had at least an incidence of 10,000 cases a year, 10 recommended regimens, and a 50% 5-year survival. In conclusion, “unmet medical need” has been used to describe cancer indications that are rare, and have few options and poor survival outcomes. However, the term has also been used to describe indications that occur commonly, have many treatment alternatives, and are clinically indolent with more encouraging expectations for survival. Some standardization is needed.

AB - The phrase “unmet medical need” has important regulatory implications, but there is no empirical analysis of its real world usage. We sought to determine the annual US incidence, 5-year survival, and number of National Comprehensive Cancer Network (NCCN)-recommended regimens for indications described in the literature as an “unmet medical need.” We queried Google Scholar to identify publications where authors used the phrase “unmet medical need” to refer to a specific cancer indication. For each indication, we investigated the annual US incidence, 5-year survival, and number of NCCN recommended regimens. We identified 237 cancer indications considered by authors an “unmet medical need.” The term was found most frequently appended to breast cancer indications comprising 30 of the 237 citations (12.7%). This was followed by lung 24/237 (10.1%), hepatocellular 18/237 (7.6%), and prostate cancer 13/237 (5.4%). In 55 of 237 (23.2%) instances where an indication was described by the authors as an unmet medical need, the incidence was 1,000 cases per year, there were five regimens recommended by NCCN, and there was a 50% or greater 5-year survival. Forty-three of 237 (18.1%) indications had at least an incidence of 10,000 cases a year, 10 recommended regimens, and a 50% 5-year survival. In conclusion, “unmet medical need” has been used to describe cancer indications that are rare, and have few options and poor survival outcomes. However, the term has also been used to describe indications that occur commonly, have many treatment alternatives, and are clinically indolent with more encouraging expectations for survival. Some standardization is needed.

KW - Cancer drug approval

KW - Regulation

KW - Unmet medical need

KW - US FDA

UR - http://www.scopus.com/inward/record.url?scp=85017145222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017145222&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2017.02.009

DO - 10.1053/j.seminoncol.2017.02.009

M3 - Article

C2 - 28395768

AN - SCOPUS:85017145222

VL - 44

SP - 8

EP - 12

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1

ER -